In July 2019, Fuzhongsheng Medical and Global Citizen Capital signed a financing framework agreement to pave the way for Fuzhongsheng Medical’s future overseas expansion.
Mr. Kenneth Kwok, President of Global Citizen Capital, said: Forallbio Technology has launched a patented blood test for multi-molecular protein therapy evaluation and monitoring on the theme of cancer and telomere structure research, which can provide cancer patients with more accurate Medical methods. The detection can detect the oncoproteins expressed on tumor cells and the telomere detection of the main structure of human cell division, expand the range of patients tested by the International Cancer Medical Center, and ensure the most appropriate method of treatment.